Brian Monahan MD, MACP

Education

Graduate / Medical Education:
Doctor of Science, honoris causa, Fairfield University, Fairfield CT, May 2011.
Research Fellow, National Cancer Institute Medicine Branch/Navy, Gastrointestinal Tumor Group, Bethesda, MD Aug 1995-Aug 1996.
Medical Oncology and Hematology Fellow, Divisions of Medical Oncology and Hematology, National Naval Medical Center, Bethesda, MD. Aug1993- Aug 1996.
Chief of Residents, Department of Internal Medicine, National Naval Medical Center, Bethesda, MD. 1991-1992.
Internal Medicine Resident, National Naval Medical Center, Bethesda, MD. 07/89-07/91 Internal Medicine Intern, National Naval Medical Center, Bethesda, MD. 06/86-07/87
Doctor of Medicine, Magna cum laude, Georgetown University School of Medicine, Washington DC. May 1986.

Undergraduate Education:
Bachelor of Science, Summa cum laude, with Honors in The College of Arts and Sciences, Fairfield University, Fairfield, CT May 1982.

Biography

RADM Brian P. Monahan, MC, USN, a native of Fairfield Connecticut, is a master of the American College of Physicians and a member of the Academy of Medicine. He is a professor of medicine and pathology at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He graduated summa cum laude from Fairfield University in 1982 and magna cum laude from Georgetown University School of Medicine in 1986. Following internship, he was assigned as battalion surgeon for the 3rd Battalion 6th Marine Regiment of the 2nd Marine Division from 1987-1989. He then completed his internal medicine training at the National Naval Medical Center where he was selected as the chief of residents and served as an internal medicine physician at the Office of Attending Physician, U.S. Capitol from 1991-1993. He completed his training in hematology and medical oncology at the National Cancer Institute and National Naval Medical Center in 1996. Monahan has served with distinction as professor and chairman of medicine at Uniformed Services University in Bethesda, Maryland.

RADM Monahan is certified by the American Board of Internal Medicine in internal medicine, hematology, and medical oncology. Through his ongoing duties at the National Cancer Institute, Monahan has served as the principal investigator on numerous clinical trials of novel anti-cancer drugs leading to innovations in colon cancer and clinical pharmacology. In the past 12 years, he has trained hundreds of oncologists now serving throughout the USA and in seven foreign nations. A pioneer in the discovery of the unexpected sudden death associated with the first non-sedating antihistamines (Seldane), he is the recipient of many teaching awards including the National Cancer Institute’s Teacher of the Year award. Monahan served as the program director for Medical Oncology and Hematology Fellowship Training for the Department of Defense National Capitol Consortium from 2000-2006. He was the Navy specialty leader for hematology and medical oncology from 2001-2008, chairman of the U. S. Military Cancer Institute Medical Oncology Program, and associate director for federal compliance and human subjects protections from 2002-2008. He has been a major contributor to the Navy human research protection programs leading transformative contributions to human subjects protections programs in the Department of Defense. He has published dozens of peer-reviewed articles, abstracts, and book chapters. Through his work in the American Society of Clinical Oncology, he was instrumental in the creation of the first national in-training competency examination in medical oncology in 2008.

RADM Monahan’s awards include the Defense Superior Service Medal, USUHS Outstanding Service Medal, Meritorious Service Medal, Joint Commendation Medal, and the Navy and Marine Corps Commendation Medal (five awards).

Career Highlights: Positions, Projects, Deployements, Awards and Additional Publications

Thomas R, Dahut W, Harold N, Grem J, Monahan BP, Liang M, Band R, Cottrell J, Llorens V, Smith J, Corse W, Arbuck S, Wright J, Chen AP, Shapiro J, Hamilton J, Allegra C, Takimoto C,” A Phase I trial and Pharmacologic Study of 9-aminocamptothecin Administered as a 120-h Infusion to Adult Cancer Patients, Cancer Chemother Pharmacol, 48:215-22, 2001

Grem JL, Quinn M, Ismail AS, Takimoto CH, Lush R, Liewehr DJ, Steinberg SM, Balis FM, Chen AP, Monahan BP, Harold N, Corse W, Pang J, Murphy RF, Allegra CJ, Hamilton JM. “Pharmacokinetics and Pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion,” Cancer Chemother Pharmacol. 47(2):117-25.2001

Grem LJ, Harold N, Shapiro J, BI DQ, Quinn M, Zentko S, Keith B, Hamilton JM, Monahan BP, Donavan S, Grollman F, Morrison G, Takimoto C,” Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given with Eniluracil and Low-Dose Leucovorin to Patients with Solid Tumors,” Journal of Clinical Onc 18:3952-3963,2000.

Representative Bibliography

Monahan BP,” Loius R Cantilena, A Pioneer in Drug Safety,” The Pharos 83(1);30-34, 2020.

Driscoll JJ, Gauerke S, Monahan BC (sic), “Mechanistic and Treatment Implications of Delta Np63 Expression in a Rare Case of Metastatic Hidradenocarcinoma,” Case Rep Oncol. 2009 Mar 14;2(1):44-52.

Bremer CT, Monahan BP,” Necrotizing Enterocolitis in Neutropenia and Chemotherapy: A Clinical Update and Old Lessons Relearned,” Current Gastroenterology Reports, 2006;8:333-341

Wright MA, Morrison G, Lin P, Leonard GD, Nguyen D, Gou X, Szabo E, Hopkins JL, Leguizamo JP, Harold N, Fioravanti S, Schuler B, Monahan BP, Saif MW, Quinn MG, Pang J, Grem JL,” A phase I pharmacologic and pharmacogenetic trial of sequential 24- hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. Clin Cancer Research 11:4144-50, 2005

Mansky PJ, Grem J, Wallerstedt DB, Monahan BP, Blackman MR,” Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for Phase I Study of Botanicals and Botanical- Drug Interactions in Cancer Therapy,” Integrative Cancer Therapies ,2:345-352, 2003.

Grem JL, Quinn MG, Keith B, Monahan BP, Hamilton JM, Xu Y, Harold N, Nguyen D, Takimoto CH, Rowedder A, Pang J, Morrison G, Chen A, “A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin.” Cancer Chemother Pharmacol. 52:487-96, 2003.

Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow D, Hamilton A, Mulkerin D, Graham G, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, and Grem JL,” Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study,” JCO 21: 2664-2672, 2003

Gou XD, Harold N, Saif MW, Schuler B, Hamilton JM, Monahan BP, Quinn MG, Cliatt J, Nguyen D, Grollman F, Thomas RR, McGuigan EA, Wilson R, Takimoto CH, Grem J,” Pharmacokinetic and Pharmacodynamic Effects of Oral Eniluracil, Fluorouracil and Leucovorin Given on a Weekly Schedule,” Cancer Chemother Pharmacol 52:79-85,2003

Leonard GD, Battiwalla M, Stockle JB, Harris RA, Monahan BP, Grem JL,” Extraoccular Muscle Palsy from Metastatic Prostate Cancer,” The Lancet (Oncology) 4:358,2003.

Grem J, Harold N, Keith B, Chen A, Kao V, Takimoto C, Hamilton J, Pang J, Pace M, Jasser G, Quinn M, and Monahan BP,” A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as Weekly 24-Hour Continuous Intravenous Infusion in Adult Caner Patients,” , Clinical Cancer Research 8:2149-2156, 2002.